US won’t hold back 2nd vaccine doses
EU considering Oxford jab
WASHINGTON, Jan 13, (AP): Barely a month into a mass vaccination campaign to stop the COVID-19 pandemic, the Trump administration unexpectedly shifted gears Tuesday to speed the delivery of shots. A slow start had triggered widespread concern from states and public health officials.
Now, Health and Human Services Alex Azar has announced two major changes. First, the government will no longer hold back required second doses of the Pfizer-BioNTech and Moderna vaccines, practically doubling supply. Second, states should immediately start vaccinating other groups lower down the priority scale, including people age 65 and older, and younger people with certain health problems.
The move better aligns the outgoing administration with the new Biden-Harris team. On Friday, President-elect Joe Biden said he will rapidly release most available vaccine doses to protect more people. He said he supported immediately releasing vaccines that health authorities were holding back out of caution, to guarantee they would be available for people needing their second dose.
“We had been holding back second doses as a safety stock,” Azar said on ABC. “We now believe that our manufacturing is predictable enough that we can ensure second doses are available for people from ongoing production. So everything is now available to our states and our health care providers.”
Simultaneously, he gave states the green light to dramatically expand the pool of people eligible to receive vaccines.
“We are calling on our governors to now vaccinate people aged 65 and over, and under age 65 with a (health condition) because we have got to expand the group,” he said.
As of Monday morning, the government had distributed about 25.5 million doses to states, US territories and major cities. But only about 9 million people had received their first shot. That means only about 35% of the available vaccines had been administered.
Initially, the shots were going to health care workers and nursing home residents. Those 75 and older were next in line. But problems arose even in vaccinating that limited pool of people. Some hospital and nursing home workers have been hesitant to get the vaccine. Scheduling issues created delays in getting shots to nursing homes.
Vaccinations
Some states, including Arizona, have or are planning to open up mass vaccination centers, aiming to inoculate thousands of people a day in a single location. In Florida, Gov. Ron DeSantis opened up vaccinations to people 65 and older. In other states, local health authorities have started asking residents 65 an older to register, in anticipation the vaccination campaign would be expanded.
“We’ve got to get to more channels of administration,” said Azar. “We’ve got to get it to pharmacies, get it to community health centers.
“We will deploy teams to support states doing mass vaccination efforts if they wish to do so,” he added.
Although Azar said the shift was a natural evolution of the Trump administration’s efforts, as recently as Friday he had raised questions about whether Biden’s call to accelerate supplies was prudent. The Trump administration, which directed a crash effort to develop and manufacture vaccines, is hoping to avoid a repeat of earlier debacles with coronavirus testing. Dubbed “Operation Warp Speed,” the effort has produced two highly effective vaccines, with more on the way.
Each state has its own plan for who should be vaccinated, based on recommendations from the federal Centers for Disease Control and Prevention. The CDC recommendations give first priority to health care workers and nursing home residents.
But the slow pace of the vaccine rollout has frustrated many Americans at a time when the coronavirus death toll has continued to rise. More than 376,000 people have died, according to the Johns Hopkins database.
US Surgeon General Jerome Adams said hundreds of thousands of people are getting vaccinated every day across the nation, but the pace of inoculations needs to improve.
“We’re in a race against this virus and quite frankly, we’re behind,” Adams told “Fox & Friends.” “The good news is that 700,000 people are getting vaccinated every single day. We’re going to hit 1 million people and we need to continue to pick up that pace.”
In Philadelphia, health department spokesman James Garrow, said the new direction from Washington will take time to figure out before it impacts vaccine distribution in the city. “This is a wholesale change out of the blue after months of planning,” Garrow said.
Washington, D.C. on Monday opened up vaccines to residents 65 years and older and the system was quickly overwhelmed. People reported problems with the website for registration and hours-long waits to register by phone. A message on the city’s website Tuesday morning read, “All 6,700 of the available vaccination appointments for the week of 1/11/21 were filled.”
Biden is expected to give a speech Thursday outlining his plan to speed vaccines to more people in the first part of his administration. His transition team has vowed to release as many vaccine doses as possible, rather than continuing the Trump administration policy of holding back millions of doses to ensure there would be enough supply to allow those getting the first shot to get a second one.
The Pfizer-BioNTech vaccine requires a second shot about three weeks after the first vaccination. Another vaccine, this one produced by Moderna, requires a second shot about four weeks afterward. One-shot vaccines are still undergoing testing.
Also:
LONDON: The European Medicines Agency said Tuesday that AstraZeneca and Oxford University have submitted an application for their COVID-19 vaccine to be licensed across the European Union.
The EU regulator said it received a request for the vaccine to be greenlighted under an expedited process and that it could be approved by Jan 29 “provided that the data submitted on the quality, safety and efficacy of the vaccine are sufficiently robust and complete.” The EMA, the drugs agency for the 27-nation EU, has already approved two other coronavirus vaccines, one made by American drugmaker Pfizer and Germany’s BioNTech and another made by US biotechnology company Moderna. Switzerland approved the Moderna vaccine on Tuesday and plans to immunize about 4% of its population using that and the Pfizer-BioNTech shot.
Britain gave its approval to the Oxford-AstraZeneca vaccine last month and has been using it. India approved it this month.
As part of its strategy to obtain as many different COVID-19 vaccines as possible for Europeans, the EU said it had concluded early talks with French biotech company Valneva to secure up to 60 million doses of vaccine.
Valneva previously signed a deal with Britain to provide tens of millions of doses of its shot, which is developed using similar technology to that used to make flu vaccines. The EU has sealed six vaccine contracts for up to 2 billion doses, many more than are necessary to cover its population of approximately 450 million.
The Oxford-AstraZeneca vaccine is expected to be a key vaccine for many countries because of its low cost, availability and ease of use. It can be kept in refrigerators rather than the ultra-cold storage that the Pfizer vaccine requires. The company has said it will sell it for $2.50 a dose and plans to make up to 3 billion doses by the end of 2021.
Researchers claim the Oxford-AstraZeneca vaccine protected against disease in 62% of those given two full doses and in 90% of those initially given a half dose because of a manufacturing error. However, the second group included only 2,741 people - too few to be conclusive.